|
|
23733 West 83rd Terrace
Shawnee, KS 66227 USA
phone:650.814.8197
fax:913-742-7773
|
|
| Symbol |
Private |
| Founded |
2006 |
| Employees |
13 |
|
|
| www.kcbiomedix.com
|
|
| Research Sector |
Medical Devices & Tech |
|
 |
| Summary Description |
| KC BioMedix, Inc. is a commercial stage medical device company developing and selling neurostimulation products that address the overwhelming problem of incompetent feeding in premature infants. There are over 500,000 infants born prematurely in the U.S. each year, and as many as 50% are suffering from the inability to breast or bottle feed. Because these patients are not discharged from the neonatal ICU until they achieve 100% oral feeding competency, they create a substantial medical, economic and emotional burden for hospitals, neonatologists, patients and their families. Our first product, the NTrainer System, solves this problem by assessing and treating their dysfunctional oral feeding, accelerating healthy development and enabling them to leave the hospital sooner. |
|
| Management |
| John Kraczkowsky, CEO; Michael Litscher, Co-founder and President; David Stalling, Co-founder and CTO;
Bruce Richardson, CFO; Monty W. Hukill, VP of Sales; |
| |
|
|
| |
|
| Keywords |
| neurostimulation therapy, NICU, pediatrics, neonatology, non-nutritive suck, infants, patient monitoring, premature, infants, pediatric, newborn, occupational therapy, PatientMonitoring |
|
|
|
| Description |
|
KC BioMedix specializes in the care and treatment of infants born prematurely.
The company offers a proprietary neurostimulation device that accelerates a premature infant's transition from tube to bottle feeding. It reduces the length of stay in the Neonatal ICU, saving up to $3,500/day. |
|
| Products / Services |
Our NTrainer System delivers pulsatile neurostimulation to accelerate the development of oral feeding skills in premature infants.
|
|
| Technology / Differentiation |
| The NTrainer neurostimulation system provides neonatologists with a diagnostic tool that enables them to properly assess an infants ability to orally feed. It monitors critical vital signs and calculates a novel new index that measures and reports the patients progress towards full oral feeding. Our Spatiotemporal Index (STI) is generated from a proprietary algorithm that is based on R01 NIH sponsored research performed over the past 10 years involving nearly 2,500 premature infants. The NTrainer then allows caregivers to provide pulsatile orocutaneous neurostimulation therapy which has been clinically proven to accelerate the development of Non Nutritive Suck (NNS). NNS is an essential neurological building block in an infants coordination of sucking, swallowing and breathing - a capability required for independent oral feeding. Without NNS, nutritive suck and therefore oral feeding is not possible. By accelerating the transition to breast or bottle feeding the NTrainer can significantly reduce a Neonatal ICU (NICU) stay, resulting in an earlier hospital discharge and, with an average cost of $2,500 to $3,500 per NICU patient per day, a substantial cost savings. The company has filed six patents with the US and European patent offices. |
|
| Market / Customers |
We sell our neurostimulation device to hospital-based neonatal intensive care units. There are over 500,000 premature infants born each year in the U.S. and over 12 million worldwide. With nearly 1,100 NICUs in the US, and company expectations of four units per NICU, the domestic market potential is 4,400 units for the first product. The NTrainer System price is $125,000 per unit - a price at which a fully utilized NTrainer will pay for itself within three months. It also has a single use disposable component that can generate over $30,000 per fully utilized unit each year. This establishes the US market at over $500 million for the system and recurring consumable revenues of $50 million per year. With the global population of premature infants being 24 times larger than the US, the company projects the global market at well over $1 billion.
|
|
| Competitors / Substitutes / Alternatives |
We know of no medical device currently available on the market or in the pipeline that assesses and treats incompetent oral feeding. First mover advantage, 6 patent applications and 4 completed clinical studies provide us with significant advantage and protection.
|
|
| Funding |
| The company has successfully completed a $1.4M seed round, a $4.0M A Round and a $1.9M convertible debt offering. We currently seek a $7M Series B round to support the following initiatives:
Expanding our direct sales channel and proceeding with a full market launch
Expanding our manufacturing capacity to handle the increased sales volume
Continuing the development of product enhancements and new products
Achieving cash flow breakeven by the mid 2012 |
|
| Status |
| Early stage commercialization seeking expansion capital to fund full product launch. |
|
|
|
|
|
|
|
Biotech & Specialty Pharma
Healthcare Services
Medical Devices & Tech
OneMedPlace Member
AdvaMed Members